CA-BE-MY-EYES
14.3.2023 18:04:39 CET | Business Wire | Press release
Be My Eyes, the mobile app that allows anyone to assist visually impaired people through live video calls, today announced Virtual Volunteer™, the first-ever digital visual assistant powered by OpenAI’s new GPT-4 language model.
The new tool from Be My Eyes integrates OpenAI’s latest generative AI technology, with the goal of providing an unprecedented level of accessibility and power to the 253 million people who are blind or have low vision globally.
“We are entering the next wave of innovation for accessibility technology powered by AI. This new Be My Eyes feature will be transformative in providing people who are blind or have low vision with powerful tools to better navigate physical environments, address everyday needs, and gain more independence,” said Mike Buckley, CEO of Be My Eyes. “We are thrilled to work with OpenAI to further our mission of improving accessibility for the 253 million people who are blind or have low-vision, with safe and accessible applications of generative AI.”
The Virtual Volunteer feature will be integrated into the existing app and contains a dynamic new image-to-text generator powered by GPT-4. Users can send images via the app to an AI-powered Virtual Volunteer, which will answer any question about that image and provide instantaneous, conversational visual assistance for a wide variety of tasks.
What sets the Virtual Volunteer tool apart from other image-to-text technology available today is the context it provides, with highly nuanced explanations and conversational abilities not yet seen in the digital assistant field. For example, if a user sends a picture of the inside of their refrigerator, the Virtual Volunteer will not only be able to correctly identify the items within, but also extrapolate and analyze what can be prepared with those ingredients. The tool can also then offer a number of recipes for those ingredients and send a step-by-step guide to prepare them.
This new feature promises to not only better support the blind and low-vision community through the Be My Eyes app, but it will also offer a way for businesses to better serve their customers by prioritizing accessibility. Be My Eyes plans to begin beta testing this with corporate customers in the coming weeks, and to make it broadly available later this year as part of the company’s Accessible CX™ offering.
Since its founding in 2015, Be My Eyes has worked to connect its 6.3 million volunteers to users to assist them with everyday tasks, and the company’s mission is to make the world more accessible for people who are blind or have low vision.
In the near future, Be My Eyes plans to apply this technology to provide people with powerful tools and capabilities to enrich their virtual assistant experience in complex ways – for example, navigating a train system in an unfamiliar place, traveling in a foreign country where translation support is needed, browsing websites and social media platforms, online shopping, and a host of other scenarios to be discovered in testing.
People who are blind or have low vision can register for the wait list in the iOS app. Just like the existing volunteer service, this tool is free for all blind and low-vision community members using the Be My Eyes app.
About Be My Eyes
Based in Denmark and launched in 2015, Be My Eyes is a global community that connects people who are blind or have low vision with sighted volunteers or company representatives. On the app, volunteers assist blind and low-vision users through a live video connection and work together to tackle challenges and handle a wide range of tasks. With the Specialized Help feature, blind and low-vision users can connect with company representatives for accessible customer support. The app harnesses the power of generosity, technology, and human connection so that people who are blind or have low vision can lead more independent lives. Be My Eyes is accessible in more than 150 countries worldwide and in over 180 languages. The app is free and available for both iOS and Android. Learn more at bemyeyes.com and join us on LinkedIn, Twitter, Facebook, Instagram, and TikTok.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom